Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device

March 14, 2018 updated by: VG Innovations, LLC

A Prospective, Single Arm Clinical Trial Evaluating Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device

The purpose of this clinical study is to evaluate fusion of the facet joints in a prospective cohort of patients utilizing the VerteLoc facet fixation device in patients receiving lumbar laminectomy (L1-S1), without ancillary stabilization devices such as pedicle and transfacet screws.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

Study Design: Non-randomized, prospective, single arm clinical trial

Patient Population and Sample Size: Patients (n=25) from up to 2 clinical site, who have been medically evaluated, found appropriate for, and have agreed to treatment by lumbar decompressive laminectomy and facet fixation, including unilateral and/or bilateral posterolateral fusion according to accepted medical standards.

Objectives:

The primary objective of this study is to:

  1. Evaluate the fusion status of facet joints following laminectomy and facet fixation using the VerteLoc system in combination with unilateral and/or bilateral posterolateral fusion.
  2. Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at 2-3 weeks, 3 months, and 12 months.

The secondary objectives of this study are to:

  1. Explore the effect of preoperative bone density on facet fusion status;
  2. Assess the ease of use of the VerteLoc system;
  3. Record operative time using the VerteLoc system;
  4. Monitor the occurrence of adverse events related or possibly related to the use of the VerteLoc system;
  5. Monitor the occurrence of subsequent surgical intervention at the target level(s).
  6. Subject success/Clinical outcome (Assess additional improvement criteria)
  7. Evaluate Fusion rate in relations to DEXA value

Inclusion Criteria: Candidates must meet ALL of the following:

  1. Have provided consent for research by signing the Institutional Review Board approved Informed Consent;
  2. Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care;
  3. Are skeletally mature, and are at least 18 years of age;
  4. If female, are not pregnant;
  5. Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.

Exclusion Criteria:

  1. Previous surgery at the target or adjacent vertebral levels;
  2. More than two intervertebral levels to be treated by the laminectomy procedure;
  3. Found to be inappropriate candidates for facet fixation using the VerteLoc system;
  4. Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables;
  5. Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses,
  6. Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery;
  7. Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
  8. BMI >40% ;
  9. History of tobacco smoking within the past 6 months;
  10. Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
  11. Are participating in any other clinical trial. Study Duration : 12 months

Study Outcomes:

The primary study outcomes of this study are:

  1. Fusion grade at 12 month follow-up using CT scans with a grading system based on:

    1. Complete fusion;
    2. Partial fusion;
    3. No fusion;
  2. Subject success / Clinical outcome:

Evaluate the reduction in baseline VAS back pain score at:

  1. 2-3 weeks
  2. 3 months
  3. 12 months.

The secondary outcomes of this study are:

  1. Statistical correlation of DEXA scan bone mass density score to CT and radiographic fusion status;
  2. Surgeon opinion of "ease of use" utilizing the VerteLoc system (0-10);
  3. Operative time (minutes) from surgical access to completion of device placement
  4. Occurrence and prevalence of adverse events related or possibly related to the use of the VerteLoc System;
  5. Occurrence of subsequent surgical intervention at the target level(s).

Study Assessments

  • Intraoperative: Post-placement radiograph;
  • 12 months: A/P and lateral flexion and extension lumbar radiograph and lumbar CT scan.

Statistical Analysis

• Student t-tests

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Michigan
      • Grand Blanc, Michigan, United States, 48439
        • Genesys Regional Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Have provided consent for research by signing the Institutional Review Board approved Informed Consent;
  2. Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care;
  3. Are skeletally mature, and are at least 18 years of age;
  4. If female, are not pregnant;
  5. Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.

Exclusion Criteria:

  1. Previous surgery at the target or adjacent vertebral levels;
  2. More than two intervertebral levels to be treated by the laminectomy procedure;
  3. Found to be inappropriate candidates for facet fixation using the VerteLoc system;
  4. Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables;
  5. Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses,
  6. Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery;
  7. Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
  8. BMI >40% ;
  9. History of tobacco smoking within the past 6 months;
  10. Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
  11. Are participating in any other clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Single Arm Study
All patients will receive treatment
Single Arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fusion grade at 12 month follow-up using CT scans
Time Frame: 12 months

Fusion grade at 12 month follow-up using CT scans with a grading system based on:

  1. Complete fusion;
  2. Partial fusion;
  3. No fusion;
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subject success / Clinical outcome
Time Frame: 2-3 weeks, 3 months and 12 months

Subject success / Clinical outcome:

Evaluate the reduction in baseline VAS back pain score.

2-3 weeks, 3 months and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lisa Guyot, MD, Ascension Genesys Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2013

Primary Completion (ANTICIPATED)

July 1, 2015

Study Completion (ANTICIPATED)

January 1, 2016

Study Registration Dates

First Submitted

July 1, 2013

First Submitted That Met QC Criteria

July 1, 2013

First Posted (ESTIMATE)

July 8, 2013

Study Record Updates

Last Update Posted (ACTUAL)

March 16, 2018

Last Update Submitted That Met QC Criteria

March 14, 2018

Last Verified

July 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • VGI-002

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spinal Stenosis

Subscribe